These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35940512)

  • 21. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis.
    Khosravi N; Stoner L; Farajivafa V; Hanson ED
    Brain Behav Immun; 2019 Oct; 81():92-104. PubMed ID: 31454519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer.
    Demark-Wahnefried W; Nix JW; Hunter GR; Rais-Bahrami S; Desmond RA; Chacko B; Morrow CD; Azrad M; Frugé AD; Tsuruta Y; Ptacek T; Tully SA; Segal R; Grizzle WE
    BMC Cancer; 2016 Feb; 16():61. PubMed ID: 26850040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
    Stearns V; Yamauchi H; Hayes DF
    Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
    Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
    Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical usefulness of circulating tumor markers].
    Ohkura H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer.
    Abramson VG; Mayer IA
    Curr Treat Options Oncol; 2011 Dec; 12(4):403-11. PubMed ID: 21918859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
    Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
    Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer].
    Letiagin VP; Vysotskaia IV
    Vestn Ross Akad Med Nauk; 1995; (4):10-4. PubMed ID: 7780332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological markers in breast cancer prognosis and treatment.
    Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
    J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting the molecular pathways involved in the effects of physical activity on breast cancers cells: A narrative review.
    Orlandella FM; De Stefano AE; Iervolino PLC; Buono P; Soricelli A; Salvatore G
    Life Sci; 2021 Jan; 265():118790. PubMed ID: 33220294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the breast ductal system in the diagnosis of cancer (review).
    Shao ZM; Liu Y; Nguyen M
    Oncol Rep; 2001; 8(1):153-6. PubMed ID: 11115588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era.
    Zhang L; Yu X; Zhou L; Yang Y; Liu S
    J BUON; 2018; 23(5):1316-1324. PubMed ID: 30570853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen.
    Hwang H; Kim J; Choi J; Kim KH; Han HS
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.